A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects.

Trial Profile

A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study of Amlodipine and Losartan Versus Two Co-administration of Amlodipine and Losartan in Healthy Caucasian Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2011

At a glance

  • Drugs Amlodipine; Amlodipine/losartan; Losartan
  • Indications Angina pectoris; Diabetic nephropathies; Heart failure; Hypertension
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Apr 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 10 Jan 2011 Hanmi Pharmaceuticals is planning to submit application for marketing approval of Amosartan in European countries in late 2011, according to a company media release.
    • 10 Jan 2011 Status changed from recruiting to completed, according to a Hanmi Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top